Psychedelic Institute of Mental Health & Family Therapy
Psychedelic Institute of Mental Health & Family Therapy
Telehealth Ketamine Therapists
⌘K
Contact
Psychedelic Institute of Mental Health & Family Therapy
ketamine

Mindfulness, music, visual occlusion in ketamine therapy for depression: do they change outcomes? A qualitative and quantitative analysis of a randomized controlled trial (Kheirkhah, et al, 2025)

"...participants in the combined sensory intervention group reported deeper engagement, a stronger sense of connection to reality, increased focus on the experience..., moments of relief from sadness, and feelings of awe and spiritual insight compared to the control group. "
Michael DeMarco, PhD

by Michael DeMarco, PhD

Mindfulness, music, visual occlusion in ketamine therapy for depression: do they change outcomes? A qualitative and quantitative analysis of a randomized controlled trial (Kheirkhah, et al, 2025)
Mindfulness, music, visual occlusion in ketamine therapy for depression: do they change outcomes? A qualitative and quantitative analysis of a randomized controlled trial - PubMed
https://clinicaltrials.gov/study/NCT05168735, identifier NCT05168735.
PubMedMina Kheirkhah

(2025):"...mindfulness, music, and eye mask made the (ketamine) experience more meaningful and emotionally rich..."..."participants in the combined sensory intervention group reported deeper engagement, a stronger sense of connection to reality, increased focus on the experience..., moments of relief from sadness, and feelings of awe and spiritual insight compared to the control group."

More like this

Ketamine/esketamine in the treatment of depression with comorbid borderline personality disorder or traits: A systematic review of effectiveness (Scott, et al, 2025)

"patients with depression and comorbid borderline personality disorder/traits were equally likely to respond to ketamine/esketamine as those with depression but without borderline personality disorder/traits."
Exploring the Therapeutic Potential of Ketamine and Psilocybin in Comparison to Current Treatment Regimens for Treatment-Resistant Depression, Mood Disorders, and Post-traumatic Stress Disorder in the Pediatric Population (Hughes, et al, 2025)

Exploring the Therapeutic Potential of Ketamine and Psilocybin in Comparison to Current Treatment Regimens for Treatment-Resistant Depression, Mood Disorders, and Post-traumatic Stress Disorder in the Pediatric Population (Hughes, et al, 2025)

"Ketamine's use for pediatric TRD demonstrated rapid-onset relief for signs and symptoms of depression in children and adolescents, and psilocybin also decreased symptoms in patients with longstanding or refractory depression. Ketamine has been well tolerated and exhibited symptom improvements"
Psychedelics and mental health: reimagining care through science, insight, and compassion (Mikellides, et al, 2025)

Psychedelics and mental health: reimagining care through science, insight, and compassion (Mikellides, et al, 2025)

"These substances are not stand-alone medications; rather, they function as adjuncts to intensive psychotherapeutic processes. Training therapists and establishing ethical, evidence-based protocols is essential."

Ketamine Reduces Suicidality-Associated Emergency Department Utilization in Patients With Treatment-Resistant Depression: A 6-Month Mirror-Image Study (Patarroyo-Rodriguez, et al, 2025)

La ketamina reduce la utilización del departamento de emergencias asociada a la suicidabilidad en pacientes con depresión resistente al tratamiento: un estudio de imagen especular de 6 meses
Vascular endothelial growth factor: a key factor in the onset and treatment of depression (Wang, et al, 2025)

Vascular endothelial growth factor: a key factor in the onset and treatment of depression (Wang, et al, 2025)

Factor de crecimiento endotelial vascular: un factor clave en la aparición y tratamiento de la depresión
Spotlight: Depression remission endures 5 years after psilocybin trial consisting of psilocybin with psychotherapy (2025)

Spotlight: Depression remission endures 5 years after psilocybin trial consisting of psilocybin with psychotherapy (2025)

"when it comes to reducing depression with psychedelic-assisted therapy, what matters even more than the drug is a strong relationship between the therapist and study participant."
Mastodon Mastodon